Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex consensus statements

JAMA Dermatology

Volumn 150, Issue 10, 2014, Pages 1095-1101

  Teng, Joyce M C ^a   Cowen, Edward W ^b   Wataya Kaneda, Mari ^c   Gosnell, Elizabeth S ^d   Witman, Patricia M ^e   Hebert, Adelaide A ^f   Mlynarczyk, Greg ^g   Soltani, Keyoumars ^h   Darling, Thomas N ⁱ  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g Santa Rosa Family and Cosmetic Dentistry   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ABLATION THERAPY; AGE; ANGIOMYOLIPOMA; ARTICLE; ASTROCYTOMA; CLINICAL EVALUATION; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; CORTICAL DYSPLASIA; CRYOSURGERY; DISEASE SURVEILLANCE; ELECTROSURGERY; EXCISION; FIBROMA; GENE; GENETIC SCREENING; GIANT CELL TUMOR; HEMANGIOFIBROMA; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LASER SURGERY; MOUTH EXAMINATION; MOUTH HYGIENE; MOUTH LESION; MUTATIONAL ANALYSIS; SCAR FORMATION; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SKIN DEFECT; SKIN EXAMINATION; SYSTEMATIC REVIEW; TREATMENT INDICATION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; COMPLICATION; ENAMEL; GENETICS; MOUTH NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; SKIN DISEASES;

AGE FACTORS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DENTAL ENAMEL; FIBROMA; HUMANS; MOUTH NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; SKIN DISEASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84908042865     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.938     Document Type: Article

References (50)

1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657-668.
2. Au KS, Northrup H. Genotype-phenotype studies in TSC and molecular diagnostics. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, eds. Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics.Weinheim, Germany: WILEY-VCH Verlag GmbH & Co KGaA; 2010:61-84.
3. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2). Lancet. 2013; 381(9869):817-824.
4. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1). Lancet. 2013;381 (9861):125-132.
5. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis. PLoS One. 2011;6(9):e23379.
6. Bissler JJ,McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.NEngl J Med. 2008;358(2):140-151.
7. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13 (12):624-628.
8. Roach ES, DiMario FJ, Kandt RS, Northrup H; National Tuberous Sclerosis Association. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. J Child Neurol. 1999;14 (6):401-407.
9. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243-254.
10. Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255-265.
11. Darling TN, Moss J, Mausner M. Dermatologic manifestations of tuberous sclerosis complex. In: Kwiatkowski DJ, Whittemore VH, Thiele EA, eds. Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics.Weinheim, Germany: WILEY-VCH Verlag GmbH & Co KGaA; 2010:285-309.
12. Sparling JD, Hong CH, Brahim JS, Moss J, Darling TN. Oral findings in 58 adults with tuberous sclerosis complex. J Am Acad Dermatol. 2007;56 (5):786-790.
13. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15(10):652-659.
14. Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifestations. PLoS One. 2013;8 (5):e63910.
15. Mlynarczyk G. Enamel pitting: a common symptom of tuberous sclerosis. Oral Surg Oral Med Oral Pathol. 1991;71(1):63-67.
16. Aldrich CS, Hong CH, Groves L, Olsen C, Moss J, Darling TN. Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J AmAcad Dermatol. 2010;63(2):244-251.
17. Carlson RM, Lloyd KM, Campbell TE. Acquired periungual fibrokeratoma: a case report. Cutis. 2007;80(2):137-140.
18. Yates JR, Maclean C, Higgins JN, et al; Tuberous Sclerosis 2000 Study Group. The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management. Arch Dis Child. 2011;96(11):1020-1025.
19. Karabiber H, Sasmaz S, Turanli G, Yakinci C. Prevalence of hypopigmented maculae and cafe-au-lait spots in idiopathic epileptic and healthy children. J Child Neurol. 2002;17(1):57-59.
20. Vanderhooft SL, Francis JS, Pagon RA, Smith LT, Sybert VP. Prevalence of hypopigmented macules in a healthy population. J Pediatr. 1996;129 (3):355-361.
21. Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas. J Clin Endocrinol Metab. 2004;89 (11):5328-5336.
22. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997;133 (7):853-857.
23. Schaffer JV, Gohara MA, McNiff JM, Aasi SZ, Dvoretzky I. Multiple facial angiofibromas: a cutaneous manifestation of Birt-Hogg-Dube syndrome. J AmAcad Dermatol. 2005;53(2)(suppl 1):S108-S111.
24. Toro JR,Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321-331.
25. Seibert D, Hong CH, Takeuchi F, et al. Recognition of tuberous sclerosis in adult women. Ann Intern Med. 2011;154(12):806-813,W-294.
26. Xia Y, Darling TN. Rapidly growing collagenomas in multiple endocrine neoplasia type I. J AmAcad Dermatol. 2007;56(5):877-880.
27. Kataoka M, Kido J, Shinohara Y, Nagata T. Drug-induced gingival overgrowth - a review. Biol Pharm Bull. 2005;28(10):1817-1821.
28. Giunta JL. Gingival fibrous nodule. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88 (4):451-454.
29. Torrelo A, Hadj-Rabia S, Colmenero I, et al. Folliculocystic and collagen hamartoma of tuberous sclerosis complex. J AmAcad Dermatol. 2012;66 (4):617-621.
30. Barron RP, Kainulainen VT, Forrest CR, Krafchik B, Mock D, Sandor GK. Tuberous sclerosis: clinicopathologic features and review of the literature. J Craniomaxillofac Surg. 2002;30(6):361-366.
31. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37(12):911-917.
32. Vincent A, Farley M, Chan E, James WD. Birt-Hogg-Dube syndrome: a review of the literature and the differential diagnosis of firm facial papules. J AmAcad Dermatol. 2003;49(4):698-705.
33. Starink TM, Houweling AC, van Doorn MB, et al. Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dube syndrome not linked to the FLCN locus. J AmAcadDermatol. 2012;66(2):259.e1-259.e9.
34. Tyburczy ME,Wang JA, Li S, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23(8):2023-2029.
35. Curatolo P, Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 2012;10(4):404-415.
36. Nashan B, Citterio F.Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94(6):547-561.
37. Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12(2):177-186.
38. Haemel AK, O'Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146(7):715-718.
39. Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165(4):912-916.
40. Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12(3):121-126.
41. Tu J, Foster RS, Bint LJ, Halbert AR. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis. Australas J Dermatol. 2014; 55(1):63-69.
42. Papadavid E, Markey A, Bellaney G,Walker NP. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol. 2002;147(2):337-342.
43. Belmar P, Boixeda P, Baniandres O, Fernandez-Lorente M, Arrazola JM. Long-term follow up of angiofibromas treated with CO2 laser in 23 patients with tuberous sclerosis [in Spanish]. Actas Dermosifiliogr. 2005;96(8):498-503.
44. Weinberger CH, Endrizzi B, Hook KP, Lee PK. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Dermatol Surg. 2009;35(11):1849-1851.
45. Weiss ET, Geronemus RG. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med. 2010;42(5): 357-360.
46. American Academy of Pediatric Dentistry, Council on Clinical Affairs. Guideline on management of dental patients with special health care needs. Pediatr Dent. 2012;34(5):160-165.
47. Eisen DB, Fazel N. Treatment of gingival fibromas using CO2 laser and electrosurgery in a patient with tuberous sclerosis. Dermatol Online J. 2008;14(11):7.
48. Korol UB, Schoor R, Nanda V, Almas K, Phelan JA. Gingival enlargement as a manifestation of tuberous sclerosis: case report and periodontal management. J Periodontol. 2008;79(4):759-763.
49. Cota LO, Aquino DR, Franco GC, Cortelli JR, Cortelli SC, Costa FO. Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus. J Clin Periodontol. 2010;37(10):894-902.
50. Pereira-Lopes O, Sampaio-Maia B, Sampaio S, et al. Periodontal inflammation in renal transplant recipients receiving everolimus or tacrolimus - preliminary results. Oral Dis. 2013;19 (7):666-672.